Pharmacological dimerization and activation of the exchange factor eIF2B antagonizes the integrated stress response

  1. Carmela Sidrauski  Is a corresponding author
  2. Jordan C Tsai
  3. Martin Kampmann
  4. Brian R Hearn
  5. Punitha Vedantham
  6. Priyadarshini Jaishankar
  7. Masaaki Sokabe
  8. Aaron S Mendez
  9. Billy W Newton
  10. Edward L Tang
  11. Erik Verschueren
  12. Jeffrey R Johnson
  13. Nevan J Krogan
  14. Christopher S Fraser
  15. Jonathan S Weissman
  16. Adam R Renslo
  17. Peter Walter
  1. University of California, San Francisco, United States
  2. Howard Hughes Medical Institution, University of California, San Francisco, United States
  3. University of California, Davis, United States

Abstract

The general translation initiation factor eIF2 is a major translational control point. Multiple signaling pathways in the integrated stress response phosphorylate eIF2 serine-51, inhibiting nucleotide exchange by eIF2B. ISRIB, a potent drug-like small molecule, renders cells insensitive to eIF2α phosphorylation and enhances cognitive function in rodents by blocking long-term depression. ISRIB was identified in a phenotypic cell-based screen, and its mechanism of action remained unknown. We now report that ISRIB is an activator of eIF2B. Our reporter-based shRNA screen revealed an eIF2B requirement for ISRIB activity. Our results define ISRIB as a symmetric molecule, show ISRIB-mediated stabilization of activated eIF2B dimers, and suggest that eIF2B4 (δ-subunit) contributes to the ISRIB binding site. We also developed new ISRIB analogs, improving its EC50 to 600 pM in cell culture. By modulating eIF2B function, ISRIB promises to be an invaluable tool in proof-of-principle studies aiming to ameliorate cognitive defects resulting from neurodegenerative diseases.

Article and author information

Author details

  1. Carmela Sidrauski

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    For correspondence
    carmelas@me.com
    Competing interests
    CS: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  2. Jordan C Tsai

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5202-722X
  3. Martin Kampmann

    Howard Hughes Medical Institution, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3819-7019
  4. Brian R Hearn

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    BRH: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  5. Punitha Vedantham

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    PV: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  6. Priyadarshini Jaishankar

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  7. Masaaki Sokabe

    Department of Molecular and Cellular Biology, College of Biological Sciences, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  8. Aaron S Mendez

    Howard Hughes Medical Institution, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  9. Billy W Newton

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  10. Edward L Tang

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  11. Erik Verschueren

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5842-6344
  12. Jeffrey R Johnson

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  13. Nevan J Krogan

    QB3, California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  14. Christopher S Fraser

    Department of Molecular and Cellular Biology, College of Biological Sciences, University of California, Davis, Davis, United States
    Competing interests
    No competing interests declared.
  15. Jonathan S Weissman

    Howard Hughes Medical Institution, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.
  16. Adam R Renslo

    Department of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, United States
    Competing interests
    ARR: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.
  17. Peter Walter

    Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, United States
    Competing interests
    PW: Inventors on UC patent application PCT/US2014/029568. Title: Modulators of the eIF2a pathway.

Funding

Howard Hughes Medical Institute (HHMI)

  • Carmela Sidrauski
  • Jordan C Tsai
  • Martin Kampmann
  • Aaron S Mendez
  • Jonathan S Weissman
  • Peter Walter

The funder had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2015, Sidrauski et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

Share this article

https://doi.org/10.7554/eLife.07314

Further reading

    1. Biochemistry and Chemical Biology
    Adrian CD Fuchs
    Research Article

    The protein ligase Connectase can be used to fuse proteins to small molecules, solid carriers, or other proteins. Compared to other protein ligases, it offers greater substrate specificity, higher catalytic efficiency, and catalyzes no side reactions. However, its reaction is reversible, resulting in only 50% fusion product from two equally abundant educts. Here, we present a simple method to reliably obtain 100% fusion product in 1:1 conjugation reactions. This method is efficient for protein-protein or protein-peptide fusions at the N- or C-termini. It enables the generation of defined and completely labeled antibody conjugates with one fusion partner on each chain. The reaction requires short incubation times with small amounts of enzyme and is effective even at low substrate concentrations and at low temperatures. With these characteristics, it presents a valuable new tool for bioengineering.

    1. Biochemistry and Chemical Biology
    2. Microbiology and Infectious Disease
    Eva Herdering, Tristan Reif-Trauttmansdorff ... Ruth Anne Schmitz
    Research Article

    Glutamine synthetases (GS) are central enzymes essential for the nitrogen metabolism across all domains of life. Consequently, they have been extensively studied for more than half a century. Based on the ATP-dependent ammonium assimilation generating glutamine, GS expression and activity are strictly regulated in all organisms. In the methanogenic archaeon Methanosarcina mazei, it has been shown that the metabolite 2-oxoglutarate (2-OG) directly induces the GS activity. Besides, modulation of the activity by interaction with small proteins (GlnK1 and sP26) has been reported. Here, we show that the strong activation of M. mazei GS (GlnA1) by 2-OG is based on the 2-OG dependent dodecamer assembly of GlnA1 by using mass photometry (MP) and single particle cryo-electron microscopy (cryo-EM) analysis of purified strep-tagged GlnA1. The dodecamer assembly from dimers occurred without any detectable intermediate oligomeric state and was not affected in the presence of GlnK1. The 2.39 Å cryo-EM structure of the dodecameric complex in the presence of 12.5 mM 2-OG demonstrated that 2-OG is binding between two monomers. Thereby, 2-OG appears to induce the dodecameric assembly in a cooperative way. Furthermore, the active site is primed by an allosteric interaction cascade caused by 2-OG-binding towards an adaption of an open active state conformation. In the presence of additional glutamine, strong feedback inhibition of GS activity was observed. Since glutamine dependent disassembly of the dodecamer was excluded by MP, feedback inhibition most likely relies on the binding of glutamine to the catalytic site. Based on our findings, we propose that under nitrogen limitation the induction of M. mazei GS into a catalytically active dodecamer is not affected by GlnK1 and crucially depends on the presence of 2-OG.